Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs MPLX LP (MPLX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs MPLX LP — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while MPLX LP trades at $58.43 (market cap $57.79B). The key difference: MPLX LP is the larger of the two by market cap, and MPLX LP pays a 7.56% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MPLX | |
|---|---|---|
Market Cap | $39.89B | $57.79B |
Sector | Health | Technology |
52-Week High | $491.22 | $59.17 |
52-Week Low | $278.09 | $47.80 |
Enterprise Value | $38.15B | $82.42B |
Dividend Yield | — | 7.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
MPLX trades at $56.95, down 0.42% on the day, with a bullish technical outlook supported by moving averages and key support at $56. The company reported strong profitability with a 41.24% net income margin and a trailing P/E of 12.33. Recent earnings showed beats in Q3 and Q4 2025 but a miss in Q1 2026, with Q2 results pending. A $1.08 dividend for H1-26 underscores its income appeal, while analyst consensus remains strongly positive with a $60.60 price target.
The outlook for MPLX is favorable, driven by stable cash flows from fee-based midstream operations and a high dividend yield. Risks include exposure to energy market volatility and a high debt-to-asset ratio of 90.06%. With 71% of analysts rating it a Buy and solid fundamentals, the stock presents a compelling opportunity for income-focused investors, though macroeconomic headwinds warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
